Bristol Myers Squibb (BMY) Liabilities from Discontinued Operations (2013)
Bristol Myers Squibb (BMY) reported Liabilities from Discontinued Operations of 4931000000.0 for Q4 2013.
Bristol Myers Squibb (BMY) Liabilities from Discontinued Operations (2013) Analysis & Trends
Bristol Myers Squibb (BMY) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 4931000000.0 in Q4 2013.
- Liabilities from Discontinued Operations for Q4 2013 came in at 4931000000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2013 was 4931000000.0 (changed N/A YoY), and the FY2013 annual result was 4931000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was little changed at 4931000000.0 in Q4 2013 per BMY's latest filing.
- Over five years, Liabilities from Discontinued Operations peaked at 4931000000.0 in Q4 2013 and troughed at 4931000000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 4.93 Bn |
| Dec 31, 2013 | 4.93 Bn |